FDA’s Mandatory GRAS Notification Proposal: What Food and Ingredient Companies Should Do Now

FDA’s mandatory GRAS notification proposal, announced on August 10, 2026, would significantly change how companies use the Generally Recognized As Safe, or GRAS, pathway for food ingredients. If finalized, the rule would move FDA’s GRAS framework away from the current voluntary notification model and toward a mandatory GRAS notification system for certain uses of substances in human and animal food.

That is a major development for ingredient suppliers, food and beverage companies, contract manufacturers, private-label brands, dietary supplement companies using food ingredients, and investors evaluating food ingredient portfolios.

It is also important to be precise about what has changed. The proposal is not a final rule. It does not automatically make every self-affirmed GRAS ingredient illegal today. It does not convert GRAS into a full food additive petition approval pathway. But it does signal that the era of quiet, undocumented, or thinly supported self-GRAS determinations is ending.

For companies that have relied on internal GRAS conclusions, supplier letters, or legacy safety files, the right response is not panic. It is a disciplined regulatory audit.

How GRAS Works Today

Under the Federal Food, Drug, and Cosmetic Act, a substance intentionally added to food is generally treated as a food additive unless it is GRAS under the conditions of its intended use or fits another exception. FDA’s current public explanation remains straightforward: GRAS uses must be supported by publicly available data, must be generally recognized by qualified experts, and must meet the same safety standard that applies to food additives: a reasonable certainty of no harm under the intended conditions of use.

Today, FDA strongly encourages companies to submit GRAS notices, but notification is not mandatory for most direct food ingredients. Companies may still reach an independent GRAS conclusion without submitting that conclusion to FDA. That self-affirmed route has long been controversial because FDA and the public may not know what substances are entering the food supply under private determinations.

FDA’s existing GRAS notice process gives the agency several possible responses. FDA may issue a "no questions" letter, may conclude that the notice does not provide a sufficient basis for a GRAS conclusion, or may cease to evaluate the notice at the notifier’s request. Under current 21 CFR 170.265, FDA generally responds within 180 days of filing a GRAS notice and may extend that timeframe by 90 days when needed.

What FDA Is Proposing

The federal regulatory agenda for RIN 0910-AJ02 describes a proposed rule titled "Substances Generally Recognized as Safe." If finalized, the rule would amend FDA’s regulations at 21 CFR Parts 170 and 570 to require submission of GRAS notices for certain uses of substances in human and animal food.

The most important proposed changes are:

• Mandatory GRAS notice submissions for certain human and animal food substance uses that companies claim are GRAS.
• A public-facing GRAS notice inventory for substances subject to mandatory notification.
• A clearer process for FDA to determine that a substance use is not GRAS.
• A presumption that covered uses are not GRAS unless the mandatory notice requirement has been satisfied.
• A possible time-limited streamlined submission pathway for substances already introduced into interstate commerce before the effective date of a final rule.

That last point matters. FDA appears to be contemplating a transition mechanism for existing marketed substances. Companies should not assume that old self-GRAS files will be grandfathered automatically. They also should not wait until the final rule is published to find out whether their safety documentation is complete.

Key Deadlines and Timing

The exact compliance dates will depend on the final rule, and the comment deadline should be confirmed from the Federal Register notice before this post is published. Based on the information currently available, companies should track the following timing points:

• August 10, 2026: FDA announced the proposed mandatory GRAS notification rule.
• Federal Register publication date and docket: not yet located in the Federal Register or Regulations.gov as of August 11, 2026. Companies should monitor the official notice and docket once posted.
• Public comment deadline: will be established in the Federal Register notice. That comment period will be the opportunity for industry to shape the final rule.
• Current GRAS notice review clock: FDA’s existing regulation provides for a 180-day response period after filing, with a possible 90-day extension.
• Final rule effective date: not yet established.
• Legacy or transition submissions: the regulatory agenda references a time-limited streamlined option for substances already in commerce before the effective date of a final rule, but the duration and eligibility criteria must be confirmed in the proposed and final rule text.

In practical terms, the deadline for companies is now. A full GRAS file audit can take weeks or months, especially where the ingredient has complex manufacturing, limited published toxicology, changing use levels, multiple suppliers, or intended uses across food categories.

Why This Proposal Matters

FDA’s proposal would increase transparency and regulatory leverage. A company that previously relied on a private GRAS conclusion may need to submit a notice, place more of its safety rationale into a public-facing system, and be prepared for FDA questions.

The business impact could be significant:

• Product launch timelines may need to account for FDA review.
• Supplier representations may need to be verified rather than accepted at face value.
• Expert panel procedures, conflict checks, and public-data support may face more scrutiny.
• Ingredient files may need to separate confidential manufacturing details from information that must be publicly available to support general recognition.
• Food companies may need to revisit whether a changed use level, new food category, altered manufacturing process, or new source material still fits the existing GRAS conclusion.

This is not simply a legal issue. It affects formulation, supply chain, quality systems, labeling, product development, contract drafting, and investor diligence.

Lessons From GRAS Notice Work

FDA Atty has worked on GRAS matters ranging from self-affirmation dossiers and public summaries to FDA GRAS notices, amendments, supplemental responses, exposure analyses, and safety narratives for food ingredients, plant proteins, animal-food ingredients, and other regulated substances. That experience includes the publicly reported hemp seed-derived ingredient notices submitted by Fresh Hemp Foods Ltd. (Manitoba Harvest), for which FDA completed its evaluation in 2018 and had no questions regarding the intended uses of hulled hemp seed, hemp seed protein powder, and hemp seed oil.

Those matters illustrate a point that will become even more important under a mandatory system: a GRAS notice is not just a label for a conclusion. It is a structured scientific and regulatory argument.

In successful GRAS work, FDA cares about the entire chain:

• What is the substance?
• How is it manufactured?
• What specifications control identity, purity, contaminants, microbes, residual solvents, allergens, and other hazards?
• What foods will contain it?
• At what use levels?
• Who will consume it, and how much?
• What public scientific evidence supports safety?
• What contrary or inconsistent evidence exists, and how is it addressed?
• Are the safety data generally available and accepted by qualified experts?
• Does the conclusion match the exact conditions of intended use?

In practice, FDA questions often focus on the areas companies underestimate: exposure assumptions, manufacturing changes, contaminant controls, allergenicity, vulnerable populations, specifications, and whether the public literature really supports the proposed conditions of use.

What Companies Should Do Now

The best preparation is a portfolio-level GRAS audit. Companies should not start with a legal conclusion. They should start with an ingredient inventory.

1. Identify every ingredient or processing aid relying on GRAS status.

For each substance, identify whether it is covered by an FDA regulation, an FDA "no questions" letter, a supplier GRAS notice, a self-affirmed GRAS dossier, a food additive regulation, a food contact notification, a prior sanction, or some other theory.

2. Match GRAS status to actual conditions of use.

A GRAS conclusion is use-specific. It may not support a different food category, higher use level, new target population, new manufacturing process, or new source material. A "GRAS ingredient" is not automatically GRAS for every use.

3. Audit the scientific support.

A defensible GRAS conclusion should include identity, manufacturing, specifications, exposure, safety narrative, literature review, discussion of inconsistent data, expert qualifications, and a clear basis for general recognition. If the dossier relies heavily on unpublished data, the company should evaluate whether the public evidence is strong enough to support GRAS status.

4. Review supplier documentation.

Supplier letters often say an ingredient is GRAS without giving the buyer enough information to evaluate the conclusion. Companies should request the underlying basis, applicable use levels, food categories, specifications, and any FDA correspondence.

5. Build a public/private information strategy.

GRAS requires public scientific support, but companies also have legitimate confidentiality interests in manufacturing details and trade secrets. A good submission strategy accounts for both.

6. Prepare for FDA questions.

FDA may ask about contaminants, analytical methods, exposure modeling, intended use categories, allergenicity, toxicology endpoints, manufacturing changes, or whether the notice duplicates or expands an existing GRAS notice. Companies should be ready to answer before the clock starts.

7. Consider submitting comments.

Industry should consider commenting on the scope of covered uses, legacy substances, streamlined transition submissions, timing, small-business burdens, confidentiality, treatment of prior "no questions" letters, FDA response categories, and how mandatory notification will interact with animal food, dietary supplements, food contact substances, and USDA/FSIS-regulated products.

Special Issues for Food, Supplements, and Animal Products

The proposal is expected to affect both human food and animal food because the regulatory agenda references 21 CFR Parts 170 and 570. Animal-food companies should pay close attention because target-animal safety and human-food safety may both matter when food-producing animals are involved.

Dietary supplement companies should also pay attention. GRAS and New Dietary Ingredient notifications are different legal pathways with different standards, evidence requirements, and timing. A substance may be positioned for conventional food use, supplement use, or both, but the regulatory strategy must be built around the intended product category.

Companies working with meat, poultry, or egg products should also consider USDA/FSIS issues. FDA may consult with USDA when a GRAS notice includes uses in products subject to FSIS regulation.

Bottom Line

FDA’s proposed mandatory GRAS notification rule is one of the most important food ingredient developments in years. It does not eliminate every existing GRAS conclusion overnight, but it changes the risk calculation.

Companies that have already built rigorous GRAS files, kept specifications current, modeled dietary exposure carefully, documented manufacturing controls, and maintained public scientific support will be in a much stronger position.

Companies relying on thin supplier statements, outdated self-affirmation memos, or incomplete safety files should move quickly. The question is no longer whether FDA will scrutinize self-affirmed GRAS. The question is whether your company can prove that its GRAS conclusion is ready for the new level of scrutiny.

FDA Atty helps food, beverage, ingredient, supplement, and animal-product companies evaluate GRAS status, prepare GRAS notices, respond to FDA questions, and build practical regulatory strategies for market access.

This article is attorney advertising and is provided for general informational purposes only. It is not legal advice and does not create an attorney-client relationship. GRAS requirements are detailed and fact-specific; consult qualified FDA regulatory counsel about your particular ingredient, product, and conditions of use.

For related FDA food compliance work, see our Food & Beverage practice page.